Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NPA and SafetyCall

This article was originally published in The Tan Sheet

Executive Summary

The Natural Products Association partners with SafetyCall adverse event reporting call center to offer association members reduced rates on reporting services in preparation for changes in reporting requirements due to the implementation of the dietary supplement AER law Congress passed in 2006, NPA announces Nov. 7 (1"The Tan Sheet" Dec. 18, 2006, p. 6). SafetyCall and NPA also plan to conduct education events to help companies comply with the regulation and "ease the transition," NPA says. "We're happy to partner with the Natural Products Association and work with their members at a time when there's a rush to conform to the new reporting requirements," SafetyCall President, Regulatory and Scientific Affairs, Richard Kingston says. "We're confident that we can meet the increased demand and quickly respond to and document adverse event reports on behalf of participating association member companies," Kingston says...

You may also be interested in...

Adverse Event System Success Will Depend On Trained Reporters, Experts Say

Training potential reporters of adverse events may be crucial to the effectiveness of a mandatory adverse event reporting system, industry stakeholders say

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts